NovAccess Global Inc. (XSNX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 62.24 Thousand USD | -50.16% |
| 2022 | 124.9 Thousand USD | -39.99% |
| 2021 | 208.13 Thousand USD | 116829.21% |
| 2020 | 178.00 USD | -99.92% |
| 2019 | 215.19 Thousand USD | 39.57% |
| 2018 | 154.18 Thousand USD | 219.25% |
| 2017 | 48.29 Thousand USD | -26.72% |
| 2016 | 65.9 Thousand USD | -30.53% |
| 2015 | 94.86 Thousand USD | 36.6% |
| 2014 | 69.45 Thousand USD | -54.16% |
| 2013 | 151.51 Thousand USD | -74.78% |
| 2012 | 600.75 Thousand USD | 194.45% |
| 2011 | 204.02 Thousand USD | -61.19% |
| 2010 | 525.67 Thousand USD | -61.79% |
| 2009 | 1.37 Million USD | -86.14% |
| 2008 | 9.92 Million USD | 72.84% |
| 2007 | 5.74 Million USD | -16.59% |
| 2006 | 6.88 Million USD | 1458.69% |
| 2005 | 441.68 Thousand USD | 512.48% |
| 2004 | 72.11 Thousand USD | 2969.99% |
| 2003 | 2349.00 USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 17.33 Thousand USD | -72.15% |
| 2024 Q3 | 273.55 Thousand USD | 219.41% |
| 2024 Q2 | 85.64 Thousand USD | 393.97% |
| 2023 Q3 | 177.02 Thousand USD | 71.11% |
| 2023 Q2 | 103.45 Thousand USD | 76.72% |
| 2023 FY | 62.24 Thousand USD | -50.16% |
| 2023 Q4 | 62.24 Thousand USD | -64.84% |
| 2023 Q1 | 58.54 Thousand USD | -53.13% |
| 2022 Q2 | 83.5 Thousand USD | 131.73% |
| 2022 Q3 | 189.43 Thousand USD | 126.85% |
| 2022 Q4 | 124.9 Thousand USD | -34.07% |
| 2022 FY | 124.9 Thousand USD | -39.99% |
| 2022 Q1 | 36.03 Thousand USD | -82.69% |
| 2021 Q1 | 7809.00 USD | 4287.08% |
| 2021 Q2 | 21.99 Thousand USD | 181.7% |
| 2021 Q3 | 25.72 Thousand USD | 16.94% |
| 2021 Q4 | 208.13 Thousand USD | 709.07% |
| 2021 FY | 208.13 Thousand USD | 116829.21% |
| 2020 Q1 | 470.96 Thousand USD | 118.86% |
| 2020 Q4 | 178.00 USD | -82.58% |
| 2020 Q2 | 208.61 Thousand USD | -55.71% |
| 2020 Q3 | 1022.00 USD | -99.51% |
| 2020 FY | 178.00 USD | -99.92% |
| 2019 Q1 | 228.48 Thousand USD | 48.19% |
| 2019 Q2 | 283.2 Thousand USD | 23.95% |
| 2019 Q4 | 215.19 Thousand USD | -30.91% |
| 2019 FY | 215.19 Thousand USD | 39.57% |
| 2019 Q3 | 311.48 Thousand USD | 9.99% |
| 2018 Q1 | 18.1 Thousand USD | -62.52% |
| 2018 Q4 | 154.18 Thousand USD | 0.4% |
| 2018 Q3 | 153.56 Thousand USD | 366.93% |
| 2018 Q2 | 32.88 Thousand USD | 81.69% |
| 2018 FY | 154.18 Thousand USD | 219.25% |
| 2017 Q3 | 124.11 Thousand USD | -40.65% |
| 2017 FY | 48.29 Thousand USD | -26.72% |
| 2017 Q4 | 48.29 Thousand USD | -61.09% |
| 2017 Q2 | 209.13 Thousand USD | 43.37% |
| 2017 Q1 | 145.87 Thousand USD | 121.35% |
| 2016 Q4 | 65.9 Thousand USD | 5.84% |
| 2016 Q1 | 106.87 Thousand USD | 12.66% |
| 2016 Q2 | 169.64 Thousand USD | 58.74% |
| 2016 Q3 | 62.26 Thousand USD | -63.3% |
| 2016 FY | 65.9 Thousand USD | -30.53% |
| 2015 FY | 94.86 Thousand USD | 36.6% |
| 2015 Q4 | 94.86 Thousand USD | 41.98% |
| 2015 Q3 | 66.81 Thousand USD | 4.6% |
| 2015 Q2 | 63.88 Thousand USD | -52.3% |
| 2015 Q1 | 133.91 Thousand USD | 92.82% |
| 2014 Q4 | 69.45 Thousand USD | -72.77% |
| 2014 FY | 69.45 Thousand USD | -54.16% |
| 2014 Q1 | 190.96 Thousand USD | 26.04% |
| 2014 Q3 | 255.08 Thousand USD | 69.48% |
| 2014 Q2 | 150.51 Thousand USD | -21.18% |
| 2013 Q1 | 582.24 Thousand USD | -3.08% |
| 2013 Q4 | 151.51 Thousand USD | -71.16% |
| 2013 FY | 151.51 Thousand USD | -74.78% |
| 2013 Q3 | 525.27 Thousand USD | -5.92% |
| 2013 Q2 | 558.31 Thousand USD | -4.11% |
| 2012 Q2 | 229.45 Thousand USD | 36.0% |
| 2012 Q4 | 600.75 Thousand USD | -1.85% |
| 2012 FY | 600.75 Thousand USD | 194.45% |
| 2012 Q3 | 612.07 Thousand USD | 166.75% |
| 2012 Q1 | 168.71 Thousand USD | -17.31% |
| 2011 Q1 | 356.87 Thousand USD | -32.11% |
| 2011 Q2 | 444.37 Thousand USD | 24.52% |
| 2011 Q3 | 436.98 Thousand USD | -1.66% |
| 2011 Q4 | 204.02 Thousand USD | -53.31% |
| 2011 FY | 204.02 Thousand USD | -61.19% |
| 2010 Q3 | 807.35 Thousand USD | -45.23% |
| 2010 FY | 525.67 Thousand USD | -61.79% |
| 2010 Q2 | 1.47 Million USD | 8.35% |
| 2010 Q4 | 525.67 Thousand USD | -34.89% |
| 2010 Q1 | 1.36 Million USD | -1.11% |
| 2009 Q1 | 12.63 Million USD | 27.27% |
| 2009 Q2 | 9.89 Million USD | -21.63% |
| 2009 FY | 1.37 Million USD | -86.14% |
| 2009 Q4 | 1.37 Million USD | -65.53% |
| 2009 Q3 | 3.99 Million USD | -59.69% |
| 2008 Q1 | 6.17 Million USD | 7.48% |
| 2008 FY | 9.92 Million USD | 72.84% |
| 2008 Q4 | 9.92 Million USD | 8.83% |
| 2008 Q3 | 9.11 Million USD | 15.52% |
| 2008 Q2 | 7.89 Million USD | 27.91% |
| 2007 Q2 | 5.72 Million USD | -8.33% |
| 2007 Q1 | 6.24 Million USD | -9.22% |
| 2007 Q4 | 5.74 Million USD | 9.03% |
| 2007 FY | 5.74 Million USD | -16.59% |
| 2007 Q3 | 5.26 Million USD | -8.06% |
| 2006 Q4 | 6.88 Million USD | -12.94% |
| 2006 Q2 | 7.95 Million USD | 348.41% |
| 2006 Q3 | 7.9 Million USD | -0.53% |
| 2006 Q1 | 1.77 Million USD | 301.4% |
| 2006 FY | 6.88 Million USD | 1458.69% |
| 2005 Q4 | 441.68 Thousand USD | 82.22% |
| 2005 Q1 | 364.09 Thousand USD | 404.89% |
| 2005 Q2 | 357.88 Thousand USD | -1.71% |
| 2005 FY | 441.68 Thousand USD | 512.48% |
| 2005 Q3 | 242.39 Thousand USD | -32.27% |
| 2004 FY | 72.11 Thousand USD | 2969.99% |
| 2004 Q2 | 8649.00 USD | 377.85% |
| 2004 Q3 | 91.64 Thousand USD | 959.6% |
| 2004 Q4 | 72.11 Thousand USD | -21.31% |
| 2004 Q1 | 1810.00 USD | -22.95% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | 2349.00 USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | 2349.00 USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | 2810.00 USD | -3.96% |
| 2001 Q3 | 810.00 USD | -71.17% |
| 2001 Q4 | - USD | -100.0% |
| 2001 Q1 | 2926.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -2594.719% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 96.821% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.41% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 88.726% |
| Rebus Holdings, Inc. | 5000.00 USD | -1144.96% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.952% |
| Qrons Inc. | 420.00 USD | -14720.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 91.923% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.777% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 87.047% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.479% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.84% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.138% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 18.474% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.942% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 95.653% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 13.981% |
| Mesoblast Limited | 667.9 Million USD | 99.991% |
| Marizyme, Inc. | 22.01 Million USD | 99.717% |
| Genus plc | 1.02 Billion USD | 99.994% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 95.417% |
| Pharming Group N.V. | 462.85 Million USD | 99.987% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 98.121% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 87.526% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 90.072% |
| ContraFect Corporation | 20.67 Million USD | 99.699% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 84.054% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 83.712% |
| IMV Inc. | 31.33 Million USD | 99.801% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 98.499% |
| MultiCell Technologies, Inc. | 126.22 USD | -49217.065% |
| ONE Bio Corp. | 70.08 Million USD | 99.911% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 93.376% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.952% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 85.581% |
| Q BioMed Inc. | 3.51 Million USD | 98.229% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.823% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 76.175% |
| Biomind Labs Inc. | 73.81 Thousand USD | 15.675% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.986% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 95.704% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.793% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 97.733% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 90.946% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 97.609% |
| GB Sciences, Inc. | 103.44 Thousand USD | 39.823% |
| Alpha Cognition Inc. | 2.45 Million USD | 97.462% |
| HST Global, Inc. | 1526.00 USD | -3979.161% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 93.699% |
| Halberd Corporation | 10.13 Thousand USD | -514.431% |
| Enzolytics Inc. | 361.7 Million USD | 99.983% |
| Agentix Corp. | 261.39 Thousand USD | 76.186% |
| Resverlogix Corp. | 8.11 Million USD | 99.233% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 96.685% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.87% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 90.269% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -173.245% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.304% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.156% |
| Zenith Capital Corp. | 7410.00 USD | -740.054% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 184.00 USD | -33730.435% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 80.657% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 76.183% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 93.292% |
| Kadimastem Ltd | 2.3 Million USD | 97.298% |
| Helix BioMedix, Inc. | 3.02 Million USD | 97.942% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.882% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.572% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -9.027% |
| LadRx Corporation | 2.3 Million USD | 97.303% |
| Cell Source, Inc. | 195.17 Thousand USD | 68.106% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 82.397% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 82.397% |
| Affymax, Inc. | 7.44 Million USD | 99.164% |
| Itoco Inc. | 1.4 Million USD | 95.554% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 34.926% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 41.275% |
| Mobile Lads Corp. | 52.00 USD | -119607.692% |
| CytoDyn Inc. | 11.13 Million USD | 99.441% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 56.461% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -248.143% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 83.851% |
| SYBLEU INC | 330.46 Thousand USD | 81.164% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 84.796% |
| International Stem Cell Corporation | 5.39 Million USD | 98.845% |
| Bioxytran, Inc. | 137.63 Thousand USD | 54.774% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.585% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.625% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 21.205% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 92.801% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.172% |
| Neutra Corp. | 2851.00 USD | -2083.374% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.808% |
| PureTech Health plc | 693.97 Million USD | 99.991% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.229% |
| IXICO plc | 15.84 Million USD | 99.607% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.248% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.94% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.981% |